Zinzino group revenue increased with a total of 18% in Q1 compared with the previous year.
The revenue in March for Zinzino's sales markets increased by 13% and amounted to SEK 135.4 (119.5) million. Faun Pharma's external sales were unchanged and amounted to SEK 9.9 (9.9) million. Overall, the Group increased revenues by 12% to SEK 145.3 (129.4) million compared with the previous year.
The group revenue increased with 18% for Q1 2023 compared with the first quarter last year and amounted to SEK 393.0 (334.4) million.
Revenues were distributed as follows:
Regions, 23 22-mar Change Q1 2023 Q1 2022 Change
mSEK -mar
The 26.0 32.8 -21% 72.8 80.3 -9%
Nordics
Central 35.4 22.2 59% 90.8 59.1 54%
Europe
East 34.6 31.5 10% 92.6 83.4 11%
Europe
South & 18.7 14.3 31% 49.0 38.1 29%
West
Europe
The 7.7 6.7 15% 21.1 18.3 15%
Baltics
North 7.1 5.4 31% 19.6 14.1 39%
America
Asia 4.5 6.1 -26% 15.6 16.4 -5%
-Pacific
Africa 1.4 0.5 180% 3.8 1.4 171%
Zinzino 135.4 119.5 13% 365.3 311.1 17%
Faun 9.9 9.9 0% 27.7 23.3 19%
Pharma
Zinzino 145.3 129.4 12% 393.0 334.4 18%
Group
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Turkey
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
marketing@zinizno.com
Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se